Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Net Margin (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Net Margin over the past 16 years, most recently at 5.62% for Q2 2025.

  • For Q2 2025, Net Margin rose 1308.0% year-over-year to 5.62%; the TTM value through May 2025 reached 34.42%, down 5362.0%, while the annual FY2025 figure was 34.42%, 4379.0% down from the prior year.
  • Net Margin for Q2 2025 was 5.62% at Lifecore Biomedical, Inc. \De\, up from 49.44% in the prior quarter.
  • Over five years, Net Margin peaked at 47.16% in Q4 2023 and troughed at 183.73% in Q2 2022.
  • A 5-year average of 33.25% and a median of 17.22% in 2022 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: tumbled -17909bps in 2022 and later skyrocketed 17639bps in 2023.
  • Year by year, Net Margin stood at 166.36% in 2021, then soared by 90bps to 16.49% in 2022, then surged by 386bps to 47.16% in 2023, then crashed by -157bps to 26.73% in 2024, then surged by 79bps to 5.62% in 2025.
  • Business Quant data shows Net Margin for LFCR at 5.62% in Q2 2025, 49.44% in Q1 2025, and 26.73% in Q4 2024.